Prospective, Multi-centre, Non-Interventional Study to Investigate the Effectiveness of REKOVELLE® for Ovarian Stimulation for Asian Women in Real World Settings
Launched by FERRING PHARMACEUTICALS · Aug 16, 2024
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how effective a medication called REKOVELLE® is for helping women in Asian countries stimulate their ovaries, which is a crucial step in assisted reproductive treatments like IVF (in vitro fertilization). The main goal is to see how well REKOVELLE® works for women who are trying it for the first time. If you are a woman aged 20 or older, have certain hormone levels that indicate your ovarian function is suitable, and are about to start your first cycle of ovarian stimulation with REKOVELLE®, you might be eligible to participate.
As a participant, you will be monitored as you undergo ovarian stimulation treatment, and your experiences will help researchers understand how REKOVELLE® performs in real-world settings. It's important to note that women who have already had more than two cycles of similar treatments or are participating in other clinical trials may not qualify for this study. If you think you might be a good fit, consider discussing it with your doctor to learn more about the trial and what participation involves.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Females aged 20 years or older at enrollment
- • Serum AMH level \>0.5 ng / mL (with the latest result tested within 12 months)
- • Who are first time prescribed REKOVELLE for their ovarian stimulation and IVF or ICSI treatment cycle using fresh or frozen ejaculated sperm from male partner or sperm donor (if applicable)
- • Willing and able to provide written informed consent
- Exclusion Criteria:
- • Have undergone more than 2 COS-IVF / ICSI cycles before the enrollment
- • Participating in an interventional clinical trial in which any medication treatment is mandated
- • Women with a contraindication for prescription of REKOVELLE treatment
- • Oocyte donors
- • Undergoing ovarian stimulation for fertility preservation
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a global biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapies that address unmet medical needs in various therapeutic areas, including reproductive health, urology, and gastrointestinal disorders. With a strong commitment to advancing healthcare through scientific excellence and patient-centered solutions, Ferring leverages its extensive expertise in hormone-related treatments and personalized medicine. The company actively engages in clinical research to develop safe and effective therapies, striving to improve the quality of life for patients worldwide while maintaining a focus on ethical practices and collaboration in the healthcare community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hiroshima, , Japan
Hokkaido, , Japan
Hyōgo, , Japan
Osaka, , Japan
Saitama, , Japan
Kitakyushu, Fukuoka, Japan
Takasaki, Gunma, Japan
Chiba, , Japan
Fukuoka, , Japan
Tokyo, , Japan
Bunkyō Ku, , Japan
Busan, , Korea, Republic Of
Taichung City, , Taiwan
Taipei, , Taiwan
Bangkok, , Thailand
Seongnam Si, Seongnam, Korea, Republic Of
Daegu, , Korea, Republic Of
Tainan, , Taiwan
Taoyuan, , Taiwan
Hanoi, , Vietnam
Ho Chi Minh City, , Vietnam
Huế, , Vietnam
Patients applied
Trial Officials
Global Clinical Compliance
Study Director
Ferring Pharmaceuticals
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported